Molecular Assays in Cytopathology for Thyroid Cancer

Valderrábano, Pablo; Zota, Victor; McIver, Bryan; Coppola, Domenico; Leon, Marino E.

doi:10.1177/107327481502200205

Cited by 11 publications

(8 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Regulation of miRNAs in thyroid tumors is an extremely complicated process with numerous factors (Valderrabano et al, 2015). We confirmed that miR-27a promotes thyroid cancer migration, invasion, and angiogenesis under both in vitro and in vivo settings.…”

Section: Discussionsupporting

confidence: 68%

Effects of miR-27a upregulation on thyroid cancer cells migration, invasion, and angiogenesis

Wang¹,

Gong²,

Yuan

2016

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Thyroid cancer is the most common type of endocrine tumor. MicroRNAs (miRNAs) play a critical role in a variety of diseases, especially cancer occurrence and progression. However, the specific mechanism by which miRNAs trigger disease states has not been fully elucidated. This study aims to investigate the role of miR-27a in thyroid cancer cells. A wound healing assay was adopted to examine cell migration. A transwell assay was applied to assess cell invasion. A thyroid cancer xenograft model was established using BALB/c nude mice. Western blot was performed to quantify iNOS expression. Tumor tissue blood vessel density was evaluated via immunohistochemistry assays. The results indicated that miR-27a downregulation inhibited thyroid cancer cell migration, while upregulation of miR-27a promoted thyroid cancer cell migration (P < 0.05). Furthermore, reduction in miR27a expression suppressed thyroid cancer cell invasion (P < 0.05). In the nude mouse model of thyroid cancer xenograft, upregulation of miR-27 induced iNOS expression in pathological tumor tissues, whereas miR27a inhibition resulted in the opposite effect (P < 0.05). CD105 level was also significantly increased during miR-27a upregulation, and was declined when miR-27a was inhibited (P < 0.05). In conclusion, miR27a upregulation in thyroid cancer cells affects tumor cell migration, invasion, and angiogenesis by targeting downstream genes. Therefore, miR27a may act as a biomarker of thyroid cancer.

show abstract

Section: Discussionsupporting

confidence: 68%

Effects of miR-27a upregulation on thyroid cancer cells migration, invasion, and angiogenesis

Wang¹,

Gong²,

Yuan

2016

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…45,46 Molecular testing has also been applied effectively in anatomic pathology; an example is in testing equivocal thyroid cytology to better triage patients for surgery. 47,48 An increasing number of these and other new tests demonstrate clinical efficacy and illustrate value for population health. 49 Screening tests are another important area of growth.…”

Section: Precision Medicinementioning

confidence: 99%

The Value Proposition for Pathologists: A Population Health Approach

Ducatman

Crawford

et al. 2020

Academic Pathology

View full text Add to dashboard Cite

The transition to a value-based payment system offers pathologists the opportunity to play an increased role in population health by improving outcomes and safety as well as reducing costs. Although laboratory testing itself accounts for a small portion of health-care spending, laboratory data have significant downstream effects in patient management as well as diagnosis. Pathologists currently are heavily engaged in precision medicine, use of laboratory and pathology test results (including autopsy data) to reduce diagnostic errors, and play leading roles in diagnostic management teams. Additionally, pathologists can use aggregate laboratory data to monitor the health of populations and improve health-care outcomes for both individual patients and populations. For the profession to thrive, pathologists will need to focus on extending their roles outside the laboratory beyond the traditional role in the analytic phase of testing. This should include leadership in ensuring correct ordering and interpretation of laboratory testing and leadership in population health programs. Pathologists in training will need to learn key concepts in informatics and data analytics, health-care economics, public health, implementation science, and health systems science. While these changes may reduce reimbursement for the traditional activities of pathologists, new opportunities arise for value creation and new compensation models. This report reviews these opportunities for pathologist leadership in utilization management, precision medicine, reducing diagnostic errors, and improving health-care outcomes.

show abstract

“…Тесты AMCs выполняются только на цитологическом материале после проведения ТАБ, содержащем подозрительный или злокачественный цитоморфологический диагноз или подозрительный результат Afirma GEC. AMCs включают изолированный профиль микроРНК для МКЩЖ и/или мутацию гена BRAF V600E для помощи в принятии дальнейшего клинического решения [47].…”

Section: диагностические панели на основе определения мутаций и уровнunclassified

MicroRNAs – promising molecular markers for detecting cancer in thyroid nodules

et al. 2018

View full text Add to dashboard Cite

Thyroid nodules are one of the most common thyroid diseases. The prevalence of thyroid nodules is estimated to be 2–65% depending on the detection methods. Yet despite the high frequency of thyroid nodules only about 5–10% of such nodules are malignant. Fine needle aspiration cytology of the thyroid nodule is currently the primary diagnostic tool for determining the nature of a thyroid nodule. Now, the fine needle aspiration biopsy is the gold standard for diagnosing thyroid cancer but in 30% of cases the cytological conclusion is uncertain. Cytological research is not enough to diagnose benign and malignant tumors. The need to improve the effectiveness of fine needle aspiration biopsy findings led to the search for new diagnostic biomarkers and the creation of diagnostic panels on their basis for their application in the diagnosis of uncertain nodules. Determination of molecular markers in the thyroid aspirate will allow to differentiate benign and malignant tumors more accurately at the preoperative stage and reduce the number of inappropriate surgery. The review article presents the characteristics of MicroRNAs, allowing them to be used in preoperative diagnosis of thyroid nodules. Diagnostic panels based on gene mutations and MicroRNA expression demonstrating high sensitivity and specificity of these methods are also indicated. Analysis of literature indicates that molecular analysis of fine needle aspiration genetic material from thyroid nodal formations demonstrates great prospects of prognosis, diagnosis and treatment of thyroid cancer. However, there is no sufficient evidence to recommend or to prohibit of utilization this molecular testing during the cytological conclusion of indeterminate thyroid nodules. Molecular analysis (MicroRNA) is a perspective method for evaluation of thyroid nodal formations with indeterminate cytology, however, this method requires further study and improvement.

show abstract

Molecular Assays in Cytopathology for Thyroid Cancer

Cited by 11 publications

References 59 publications

Effects of miR-27a upregulation on thyroid cancer cells migration, invasion, and angiogenesis

Effects of miR-27a upregulation on thyroid cancer cells migration, invasion, and angiogenesis

The Value Proposition for Pathologists: A Population Health Approach

MicroRNAs – promising molecular markers for detecting cancer in thyroid nodules

Contact Info

Product

Resources

About